Streetbeat News

Products Services

BWV

RHHBY

Blue Water Biotech Inc (NASDAQ:BWV) has released encouraging preclinical data for its monkeypox vaccine candidate, developed using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform. The vaccine candidate has shown potential in neutralizing the vaccinia virus, which is closely related to monkeypox. Meanwhile, Roche Holdings AG's (OTC:RHHBY) cobas MPXV has received FDA Emergency Use Authorization for detecting monkeypox DNA.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 5:51 pm

DASH

DoorDash Inc (NYSE:DASH) has announced major updates to its consumer app and new options for its workers, known as Dashers. The app updates, based on customer feedback, aim to improve convenience and reliability, and include expanded grocery and retail delivery options, a universal search feature, a browse tab, and a multiple carts option. Dashers now have the option to choose how they earn their pay: by offer or by time. The changes are expected to roll out gradually over the next few months.

Portfolio Pulse from Adam Eckert

June 28, 2023 | 5:47 pm

NFLX

PARA

PARAA

Netflix Inc (NASDAQ:NFLX) has added the film 'Titanic' back to its library, causing outrage among fans due to the timing of the addition, which coincides with a recent tragic submarine disaster at the Titanic wreckage site. The licensing deal for the movie to air on Netflix was struck months in advance. The film is one of the most well-known titles of Paramount Global (NASDAQ:PARA)(NASDAQ:PARAA).

Portfolio Pulse from Chris Katje

June 28, 2023 | 5:28 pm

VIRX

Viracta Therapeutics Inc (NASDAQ:VIRX) announced that their pivotal NAVAL-1 clinical trial for relapsed or refractory EBV+ peripheral T-cell lymphoma (R/R EBV+ PTCL) has met the pre-specified efficacy threshold for advancement to Stage 2. The decision is based on achieving a predetermined minimum number of objective responses within the first ten enrolled patients. The company's shares are up 5.5% at $1.51.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 4:52 pm

ASTS

CGTX

KLR

NERV

SONN

TOVX

US stocks traded mixed with the Nasdaq Composite gaining over 80 points. U.S. crude oil inventories dropped by 9.603 million barrels, more than the market estimates of a 1.757 million decline. Kaleyra, Inc. (KLR), Minerva Neurosciences, Inc. (NERV), and Theriva Biologics, Inc. (TOVX) saw their shares rise after various positive announcements. Meanwhile, AST SpaceMobile, Inc. (ASTS), Sonnet BioTherapeutics Holdings, Inc. (SONN), and Cognition Therapeutics, Inc. (CGTX) saw their shares drop due to various negative announcements.

Portfolio Pulse from Lisa Levin

June 28, 2023 | 4:22 pm

MNMD

HC Wainright has released a note stating that Mind Medicine's MM-120 appears ready to excel in Phase 2b Anxiety Trial. They believe the underappreciated MM-120 could become a blockbuster anxiety treatment and have given the company a buy rating with a $75 price target.

Portfolio Pulse from Happy Mohamed

June 28, 2023 | 4:17 pm

GOOG

The article lists the top 10 cannabis shops in San Francisco, based on Google's star ratings. The ratings are derived from consumer reviews. The shops offer a variety of cannabis products for both medical and recreational use. The article also mentions the Benzinga Cannabis Capital Conference, a major cannabis business event.

Portfolio Pulse from Jelena Martinovic

June 28, 2023 | 3:49 pm

BLNK

Blink Charging Co (NASDAQ:BLNK) plans to incorporate the North America Charging Standard (NACS) and Combined Charging System (CCS) into its charging products line. The company will start producing NACS DCFC chargers by October 2023 and will also include NACS in its Level 2 chargers, which account for about 90% of EV charging use in the U.S. The company's shares are trading higher by 2.9% at $5.51.

Portfolio Pulse from Shivani Kumaresan

June 28, 2023 | 3:45 pm

FHTX

Foghorn Therapeutics has announced data from a Phase 1 study of FHD-286 in metastatic uveal melanoma, validating its safety and tolerability. However, the company will not pursue FHD-286 for this condition. Instead, Foghorn plans to initiate a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients. Earlier this month, the FDA lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia and myelodysplastic syndrome.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 3:44 pm

WDAY

Workday Inc (NASDAQ:WDAY) has been identified by RBC Capital Markets analyst Rishi Jaluria as having a 'long runway of growth' with more than 20% subscription growth expected. The company's expansion from core HR into financials, coupled with a successful evolution into a multi-product platform, is likely to drive this growth. Jaluria initiated coverage of Workday with an Outperform rating and a price target of $275.

Portfolio Pulse from Priya Nigam

June 28, 2023 | 3:42 pm